Portage Biotech, Compedica enter mutual subscription agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Should l Buy ?
Portage Biotech and Compedica Holdings Agreement: Portage Biotech has entered a Subscription Agreement with Compedica Holdings, issuing 625,000 ordinary shares at $8.00 each in exchange for 1,165,501 shares of Compedica, valued at $4.29 per share, totaling $5 million.
Ownership and Future Funding Plans: Following the transaction, Compedica will hold 27.4% of Portage's ordinary shares, and Portage plans to allocate at least 50% of net funds from future equity arrangements to invest in Compedica equity to support its device development and commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
